We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 to be contacted about future studies.
Comparing Fingerstick Blood Glucose Monitoring versus Continuous Glucose Monitoring in Primary Care (The “GluCoCare” Study: GLUcose monitoring COmparison in primary CARE)
Principal Investigator: Richard Bergenstal, MD, Thomas Martens, MD
Study sponsor: Patient-Centered Outcomes Research Institute
Location: 10 select Primary Care Clinics across the HealthPartners network
Purpose of study: Your primary care clinic providers are partnering with the International Diabetes Center to invite you to join the GluCoCare study, a study looking at how using fingerstick blood glucose monitoring (BGM) compares to using continuous glucose monitoring (CGM) to manage type 2 diabetes in people using insulin.
In case you’re not familiar with a CGM, it is a device used to measure your glucose level every few minutes, 24 hours a day. CGM lets you see your current glucose level and shows you if your glucose is going up, down or staying steady. You can also see daily glucose patterns over time.
While it is known that controlling blood glucose is important in managing diabetes, especially when using insulin, it is not yet known which of the two ways to measure blood glucose is better. This important study will help people with type 2 diabetes know which method of measuring glucose is more helpful in improving glucose levels and decreasing the work of managing diabetes. We’re hoping you’ll partner with us to learn if using BGM or CGM is better to help manage blood glucose.
Inclusion Criteria:
This study is accepting individuals ages 18-75 who:
– Have type 2 diabetes
– Have a hemoglobin A1c 7.5-12
– Currently use insulin
– Are not currently using continuous glucose monitoring
– Currently receiving care at one of 30 clinics within the HealthPartners system
– Meet other study specific requirements
Participants will receive compensation for completed study visits up to a total of $250 if all visits are completed.
If you are interested in participating and would like to see if you are eligible, please click here to answer some eligibility questions.
Study Contact:
GluCoCare Team
(952) 967-5805
Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes (FLASH)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Abbott Diabetes Care
Location: International Diabetes Center
Purpose of study: The goal of this study is to decrease the amount of time that a person with type 2 diabetes spends with blood glucose in high ranges through the use of a continuous glucose monitoring (CGM) system. The study will help participants focus on changing their food choices and other behaviors that can have an effect on glucose. All participants in the study will be provided with the FreeStyle Libre CGM system. This CGM system is FDA approved and currently available for use. It has a sensor that measures a person’s glucose level continuously. Participants in this study will either use the FreeStyle Libre CGM system alone, or in combination with a new smartphone app that is used to log and understand the effect of foods on glucose.
Inclusion Criteria: The study is accepting males and females ages 18 and older who:
-Have type 2 diabetes
-Are taking at least 1 medication (non-insulin) to treat their diabetes
-Have an AIC between 7.5-12.0%
-Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Medtronic
Location: International Diabetes Center
Purpose of study: The purpose of this study is to see how well the Minimed 780G insulin pump system works to automatically infuse insulin for control of glucose levels for people with type 2 diabetes who use insulin. This Medtronic MiniMed 780G system consists of an insulin pump, a glucose sensor, a transmitter, and a glucose meter. The system uses continuous glucose readings from the sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 2 diabetes. The MiniMed 780 System and related supplies are provided for use during the study at no cost to qualifying participants.
Involvement in the trial will include:
• Compensation for completed study visits
• Diabetes management and education, support and guidance by diabetes professionals
• Study-related medical care, including regular health checks and lab tests provided at no cost to you
Inclusion Criteria:
The study is accepting individuals ages 18-80 who:
– Have had type 2 diabetes for 2 years or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home (Medtronic 304)
Principle Investigator: Anders Carlson, MD
Study Sponsor: Medtronic Minimed
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to look at the safety and effectiveness of the hybrid closed loop (HCL) insulin pump system, MiniMed 770G, used in a home setting by people with type 1 diabetes. This system consists of an insulin pump, a Medtronic glucose sensor, an insertion device for the sensor, a transmitter and a glucose meter. The HCL uses continuous glucose sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 1 diabetes. The MiniMed 770G has been approved by the FDA for use in the United States for ages 2 and older. Study participants will be randomly assigned so that about half will use the insulin pump in the HCL mode. The other half will either continue with multiple daily injections, if that is what they are currently using, or use the MiniMed 770G either with CGM (but without HCL mode) depending on their pre-study therapy. After about 6 months, all participants will use the insulin pump in the HCL mode using the continuous glucose monitor sensor.
Inclusion Criteria:
– 65-80 years old
– Have had type 1 diabetes for 3 months or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@ParkNicollet.com
Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2)
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Novo Nordisk
Location: International Diabetes Center
Phase of Study: III
Purpose of study: This study will look at differences in the amount of weight loss for people with type 2 diabetes who are either using a new investigational medication or a placebo (a placebo doesn’t contain any medication). Cagrilintide and semaglutide are medicines that help people lose weight. CagriSema has both cagrilintide and semaglutide in it. CagriSema may help people to lose more weight than diet and physical activity alone. Researchers will look at this in this study. Participants in the study will be randomly assigned to take either the investigational medication or placebo, while continuing to take their usual diabetes medications. All participants will also receive individual counselling sessions with study staff about healthy food choices and physical activity.
Involvement in the trial will include:
• Study medication provided at no cost
• Glucose meter and supplies used during the study, provided at no cost
• Compensation for time and travel for completed study visits
• Diabetes management, weight loss counselling and guidance by diabetes and nutrition professionals
• Study-related medical care, including regular health checks and lab tests, eye exams, EKGs provided at no cost
Inclusion Criteria:
The study is accepting individuals ages 18 and older who:
– Have type 2 diabetes
– Are either taking medications for their diabetes or are using diet and exercise for treating their diabetes
– Have an A1C less than or equal to 10%.
– Meet other study specific requirements
Exclusion Criteria:
– Use of insulin or medications for diabetes that are consider GLP-1 receptor agonists (glucagon-like peptide)
– Use of medications for weight loss
– Other study specific exclusions apply
Study Contact:
Caitlin Moening
(952) 993-6705
IDCResearch@parknicollet.com
Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1)
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Novo Nordisk
Location: International Diabetes Center
Phase of Study: III
Purpose of study: We are doing this study to see how the new medicine IcoSema controls blood sugar levels in people with type 2 diabetes. IcoSema is a medication taken once a week and is a combination of insulin icodec and another medication called semaglutide. The study will also look at how well IcoSema reduces body weight and reduces the risk of low blood sugar level (hypoglycemia). Study participants will receive either IcoSema or insulin icodec and this will be used in place of participants’ usual long-acting insulin during the study.
Participants will be provided with:
• Compensation for completed study visits
• Study medication
• Blood glucose meter and supplies
• Study-related medical care and lab tests
• Diabetes management and education, support and guidance provided by diabetes professionals
Inclusion Criteria:
The study is accepting individuals ages 18 and older who:
– Have type 2 diabetes
– Use long-acting insulin, 1-2 injections a day
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Weight Loss Wizard: Patient Perspective Interviews (Weight Loss Wizard)
Principal Investigator: Patrick O’Connor, MD, MPH, MA
Study sponsor: NIH/NIDDK
Location: Enrolled participants do not need to travel
Purpose of study: The Weight Loss Wizard participant interview is supported by National Institutes of Health to gather input from patients about their experiences with talking to their primary care doctors about weight loss options. The information gathered will help guide design and content of a shared decision-making tool used at the point of care. The interview is being offered via phone or conference call to patients with Type 2 Diabetes.
Inclusion Criteria:
-Patients with Type 2 Diabetes
Exclusion Criteria:
-Previous metabolic bariatric surgery
Study Contact:
Center for Evaluation and Survey Research
(952) 967-6912
WeightLossWizard@HealthPartners.com
